home-slider-01
4 Generations of Knowledge
3 Decades of Investing in Innovation
usvp-home3
We Help Entrepreneurs Build Market Leaders
usvp-home2

Focused on Early Stage IT and Healthcare Investments

usvp-home4

A Network of 400 Companies and 4,000 Executives

Play Video

USVP IN NUMBERS

$3.9B

Total Invested

493

Companies

88

IPOs

NEWS

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
November 5, 2019

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
GlobeNewswirePress
Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder
November 4, 2019

Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder

Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder
Okami MedicalPress
ShiraTronics, Inc. Completes $33M Million Series A Financing
October 24, 2019

ShiraTronics, Inc. Completes $33M Million Series A Financing

ShiraTronics, Inc. Completes $33M Million Series A Financing
Cision PR NewswirePress